Ingevity Corp (NGVT)
Official siteBASIC MATERIALS • SPECIALTY CHEMICALS • NYSE
Market Cap: $2.08B
Last updated: Nov 17, 2026 at 11:06 AM ET
Ingevity Corp (NGVT) Earnings: Report Dates and Results
Ingevity (NGVT) is expected to report earnings on Feb 23, 2027. In the quarter ended Sep 30, 2026, Ingevity reported EPS of $1.63, above the $1.56 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
NGVT has an expected report date of Feb 23, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 41.3% above the $0.63 reported for the quarter ended Dec 31, 2025.
NGVT Earnings Call
The latest NGVT earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, NGVT beat 33, missed 6 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $305.10M, down 8.4% from $333.10M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $1.63 | $1.56 | $1.54 - $1.64 | +4.49% | Beat | +24.4% | 3 | 2 up, 0 down | Nov 4, 2026 | $305.10M |
| Jun 30, 2026 | $1.74 | $1.31 | $1.24 - $1.43 | +32.82% | Beat | +25.2% | 3 | 0 up, 3 down | Jul 29, 2026 | $314.10M |
| Mar 31, 2026 | $1.15 | $0.83 | $0.76 - $0.90 | +38.55% | Beat | +16.2% | 3 | 1 up, 1 down | May 6, 2026 | $258.00M |
| Dec 31, 2025 | $0.63 | $0.69 | $0.50 - $0.74 | -8.28% | Miss | -33.7% | 3 | 0 up, 1 down | Feb 25, 2026 | $185.40M |
| Sep 30, 2025 | $1.31 | $1.35 | $1.15 - $1.72 | -2.96% | Miss | +19.1% | 4 | 0 up, 1 down | Nov 5, 2025 | $333.10M |
| Jun 30, 2025 | $1.39 | $1.16 | $1.00 - $1.36 | +19.83% | Beat | +37.6% | 4 | 0 up, 1 down | Aug 4, 2025 | $331.50M |
| Mar 31, 2025 | $0.99 | $0.74 | $0.65 - $0.95 | +33.78% | Beat | +90.4% | 4 | 1 up, 0 down | May 5, 2025 | $247.90M |
| Dec 31, 2024 | $0.95 | $0.31 | $0.12 - $0.48 | +208.94% | Beat | +352.4% | 4 | 2 up, 0 down | Feb 18, 2025 | $135.60M |
| Sep 30, 2024 | $1.10 | $0.90 | $0.60 - $1.15 | +22.22% | Beat | -9.1% | 4 | 0 up, 0 down | Oct 29, 2024 | $333.80M |
| Jun 30, 2024 | $1.01 | $1.04 | $1.00 - $1.11 | -2.88% | Miss | -28.4% | 5 | 0 up, 0 down | Jul 31, 2024 | $390.60M |
| Mar 31, 2024 | $0.52 | $0.25 | $0.08 - $0.88 | +108.00% | Beat | -52.3% | 6 | 2 up, 0 down | May 1, 2024 | $340.10M |
| Dec 31, 2023 | $0.21 | -$0.19 | -$0.25 - -$0.06 | +210.53% | Beat | -63.2% | 6 | 0 up, 0 down | Feb 21, 2024 | N/A |
| Sep 30, 2023 | $1.21 | $1.23 | $1.10 - $1.39 | -1.63% | Miss | -42.1% | 6 | 1 up, 0 down | Nov 1, 2023 | $446.00M |
| Jun 30, 2023 | $1.41 | $1.38 | $1.08 - $1.53 | +2.17% | Beat | -18.5% | 7 | 0 up, 0 down | Aug 2, 2023 | $481.80M |
| Mar 31, 2023 | $1.09 | $1.11 | $0.93 - $1.46 | -1.80% | Miss | -32.7% | 7 | 0 up, 0 down | May 3, 2023 | $392.60M |
| Dec 31, 2022 | $0.57 | $0.87 | $0.64 - $0.96 | -34.48% | Miss | -26.9% | 7 | 0 up, 0 down | Feb 27, 2023 | $383.60M |
| Sep 30, 2022 | $2.09 | $1.69 | $1.45 - $2.00 | +23.67% | Beat | +29.0% | 6 | 0 up, 0 down | Nov 2, 2022 | $482.00M |
| Jun 30, 2022 | $1.73 | $1.62 | $1.50 - $1.80 | +6.79% | Beat | +11.6% | 7 | 0 up, 1 down | Aug 2, 2022 | $419.90M |
| Mar 31, 2022 | $1.62 | $1.04 | $0.88 - $1.26 | +55.77% | Beat | +27.6% | 7 | 0 up, 0 down | May 4, 2022 | $382.80M |
| Dec 31, 2021 | $0.78 | $0.78 | $0.61 - $0.99 | 0.00% | In line | -41.4% | 8 | N/A | Feb 23, 2022 | $336.00M |
| Sep 30, 2021 | $1.62 | $1.54 | $1.35 - $1.71 | +5.19% | Beat | -9.5% | 8 | 0 up, 1 down | Oct 27, 2021 | $376.80M |
| Jun 30, 2021 | $1.55 | $1.32 | $0.98 - $1.53 | +17.42% | Beat | +146.0% | 8 | N/A | Jul 28, 2021 | $358.40M |
| Mar 31, 2021 | $1.27 | $1.03 | $0.88 - $1.17 | +23.30% | Beat | +13.4% | 7 | N/A | Apr 28, 2021 | $320.30M |
| Dec 31, 2020 | $1.33 | $0.77 | $0.56 - $1.21 | +72.73% | Beat | +20.9% | 8 | N/A | Feb 10, 2021 | $325.60M |
| Sep 30, 2020 | $1.79 | $1.01 | $0.78 - $1.18 | +77.23% | Beat | +22.6% | 9 | N/A | Oct 20, 2020 | $331.70M |
| Jun 30, 2020 | $0.63 | $0.60 | $0.53 - $0.72 | +5.00% | Beat | -53.7% | 9 | N/A | Jul 29, 2020 | $270.60M |
| Mar 31, 2020 | $1.12 | $0.82 | $0.70 - $0.93 | +36.59% | Beat | +13.1% | 8 | N/A | Apr 29, 2020 | $288.20M |
| Dec 31, 2019 | $1.10 | $1.07 | N/A | +2.80% | Beat | +2.8% | 9 | N/A | Feb 3, 2020 | $303.40M |
| Sep 30, 2019 | $1.46 | $1.40 | $1.35 - $1.46 | +4.29% | Beat | +25.9% | 9 | N/A | Oct 23, 2019 | $359.90M |
| Jun 30, 2019 | $1.36 | $1.33 | $1.23 - $1.40 | +2.26% | Beat | +21.4% | 8 | N/A | Jul 24, 2019 | $352.80M |
| Mar 31, 2019 | $0.99 | $0.98 | $0.89 - $1.05 | +1.02% | Beat | +25.3% | 8 | N/A | May 1, 2019 | $276.80M |
| Dec 31, 2018 | $1.07 | $0.77 | $0.71 - $0.84 | +38.96% | Beat | +137.8% | 7 | N/A | Feb 13, 2019 | $278.60M |
| Sep 30, 2018 | $1.16 | $1.04 | $0.94 - $1.13 | +11.54% | Beat | +34.9% | 7 | N/A | Oct 24, 2018 | $311.20M |
| Jun 30, 2018 | $1.12 | $1.00 | $0.85 - $1.10 | +12.00% | Beat | +43.6% | 7 | N/A | Jul 25, 2018 | $308.60M |
| Mar 31, 2018 | $0.79 | $0.63 | $0.54 - $0.76 | +25.40% | Beat | +61.2% | 7 | N/A | May 2, 2018 | $235.20M |
| Dec 31, 2017 | $0.45 | $0.36 | $0.29 - $0.43 | +25.00% | Beat | +32.4% | 7 | N/A | Feb 20, 2018 | $229.50M |
| Sep 30, 2017 | $0.86 | $0.76 | $0.72 - $0.78 | +13.16% | Beat | +34.4% | 7 | N/A | Nov 1, 2017 | $264.10M |
| Jun 30, 2017 | $0.78 | $0.70 | $0.66 - $0.74 | +11.43% | Beat | +18.2% | 7 | N/A | Aug 2, 2017 | $260.30M |
| Mar 31, 2017 | $0.49 | $0.47 | N/A | +4.26% | Beat | +151.5% | N/A | N/A | May 3, 2017 | $218.50M |
| Dec 31, 2016 | $0.34 | $0.30 | N/A | +13.33% | Beat | N/A | N/A | N/A | Feb 22, 2017 | $210.90M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $4.32, up 20.7% from the year before. It was $1.83 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $4.32 | +20.7% |
| Dec 31, 2024 | $3.58 | -8.7% |
| Dec 31, 2023 | $3.92 | -34.8% |
| Dec 31, 2022 | $6.01 | +15.1% |
| Dec 31, 2021 | $5.22 | +7.2% |
| Dec 31, 2020 | $4.87 | N/A |
| Dec 31, 2019 | $4.91 | +18.6% |
| Dec 31, 2018 | $4.14 | +60.5% |
| Dec 31, 2017 | $2.58 | +40.6% |
| Dec 31, 2016 | $1.83 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,300 words across 8 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,312 | 8 | |
| 2026Q2 | Jun 30, 2026 | 4,039 | 7 | |
| 2026Q1 | Mar 31, 2026 | 3,387 | 7 | |
| 2025Q4 | Dec 31, 2025 | 4,571 | 8 | |
| 2025Q3 | Sep 30, 2025 | 3,116 | 8 | |
| 2025Q2 | Jun 30, 2025 | 4,371 | 8 | |
| 2025Q1 | Mar 31, 2025 | 4,144 | 7 | |
| 2024Q4 | Dec 31, 2024 | 4,633 | 9 |
2026Q3 Earnings Call
Opening remarks
Michael H. Walsh Head of Investor Relations Thank you, and good morning. Welcome again to Ingevity's third quarter 2026 earnings call. Last evening, we posted a presentation on our investor site that you can use to follow today's discussion. It may be found on our website, ir.ingevity.com, under Events and Presentations. Throughout this call, we may refer to non-GAAP financial measures, which are intended to supplement, not substitute for, comparable GAAP measures. Definitions of these measures and reconciliations to comparable GAAP measures are included in our earnings materials. We may also make forward-looking statements regarding future events and the company's future financial performance. Actual results or events may differ materially from those projections. Please refer to the forward-looking statements and risk factors described in our earnings release and SEC filings. The agenda for today's call is listed on slide 3. Today, you will hear from David H. Li, our CEO and President, and Phillip John Platt, our CFO. Our prepared comments will focus on third quarter results and recent business highlights. Following the prepared remarks, we will take questions related to the quarter during the Q&A session. With that, I would now like to turn the call over to David.
David H. Li CEO and President Thank you, Mickey, and good morning, everyone. Please turn to slide 4. Our third quarter performance demonstrates the resilience of our business and the progress we are making across Ingevity. We delivered strong margins and cash generation while advancing the strategic priorities that are building a more focused, higher-performing specialty materials company. Performance Materials delivered another strong quarter, supported by North American automotive demand amid the ongoing shift toward hybrid vehicles, along with growth in filtration. Advanced Polymer Technologies improved profitability through a more favorable product mix, and in Pavement Technologies, higher asphalt costs resulted in softer demand and elevated input and operating costs. Another highlight this quarter was the continued momentum in our organic growth efforts, particularly in filtration, where we are seeing tangible progress toward building a scalable platform. In water treatment, we continue to receive strong interest from customers seeking effective solutions for PFAS removal. Last quarter, we announced our first commercial win, and since then, we have secured several more contracts. Activity in this area continues to accelerate as more municipalities look to address their PFAS levels ahead of required reporting in early 2027, and we believe our materials will play an important role in solving this critical water challenge. Another example of our progress in filtration is in biogas purification, where commercial adoption and project activity continue to accelerate in 2026. Our differentiated solutions are helping renewable natural gas producers remove contaminants and improve production output, creating tangible value for customers.
Frequently Asked Questions About NGVT
When is Ingevity's next earnings date?
Ingevity's next earnings report is expected for Feb 23, 2027.
Did NGVT beat earnings estimates last quarter?
Yes. Ingevity reported EPS of $1.63 for the quarter ended Sep 30, 2026, above the $1.56 estimate, a 4.49% surprise.
What EPS do analysts expect from NGVT next quarter?
The consensus EPS estimate for Ingevity for the quarter ending Dec 31, 2026 is $0.89 from 5 analysts, with estimates from $0.76 to $1.01.
How often does NGVT beat earnings estimates?
Ingevity beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +40.90%.
NGVT pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors